Atara Biotherapeutics, Inc. (ATRA) earnings
ATRA earnings moved a median of +1.82% by the close. Quarterly and annual ATRA reports and results, each read against the price at its own news timestamp. Back to the ATRA overview →
19 measured ATRA earnings events.
Where these ATRA earnings landedvs 18 measured ATRA earnings reactions
| Middle 50% of ATRA earnings reactions | -6.25% to +3.99% |
|---|---|
| Median reaction (to close) | +1.82% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 ATRA earnings events with a measured close landed between -6.25% and +3.99%; 61% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress | Press release | -3.36% | +2.04% | |
| Form 10-Q Atara Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | -3.36% | +2.04% | |
| Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress | Press release | +9.00% | +13.67% | |
| Form 10-Q Atara Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | +9.00% | +13.67% | |
| Form 10-K Atara Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | -4.53% | -8.88% | |
| Form 10-Q Atara Biotherapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.25% | +0.89% | |
| Form 10-Q Atara Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.00% | — | |
| Form 10-Q Atara Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | -6.24% | +1.60% | |
| Form 10-K Atara Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.29% | -10.98% | |
| Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress | Press release | +14.66% | +17.85% | |
| Form 10-Q Atara Biotherapeutics, For: Sep 30 | SEC filing · Form 10-Q | +14.66% | +17.85% | |
| Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 | Press release | -2.85% | -6.58% | |
| Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update | Press release | -3.85% | +2.82% | |
| Form 10-Q Atara Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | -3.85% | +2.82% | |
| Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress | Press release | +1.73% | -7.04% | |
| Form 10-Q Atara Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.73% | -7.04% | |
| Form 10-K Atara Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.05% | +4.38% | |
| Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results | Press release | -3.75% | -5.26% | |
| Form 10-Q Atara Biotherapeutics, For: Sep 30 | SEC filing · Form 10-Q | -3.75% | -5.26% |
Keep exploring
More ATRA: analyst actions → · SEC filings → · ATRA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CYTRX CORP (CYTR) | 821 | -0.00% | 43% |
| Sinovac Biotech, Ltd. - Ordinary Shares (Antigua/Barbudo) (SVA) | 814 | 0.00% | 46% |
| Ionis Pharmaceuticals, Inc. (IONS) | 811 | +0.02% | 52% |
| Applied Genetic Technologies Corporation (AGTC) | 805 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.